IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $15.00 | Outperform | Leerink Partners |
| 9/5/2024 | $5.00 | Neutral | H.C. Wainwright |
| 5/3/2024 | $26.00 | Overweight | Piper Sandler |
| 10/10/2023 | $10.00 | Buy | Ladenburg Thalmann |
| 8/25/2023 | $17.00 | Outperform | Oppenheimer |
| 6/22/2023 | $20.00 | Buy | Guggenheim |
| 6/14/2023 | $14.00 | Buy | Chardan Capital Markets |
| 5/24/2023 | $20.00 | Strong Buy | Raymond James |
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
SC 13G - Zura Bio Ltd (0001855644) (Subject)
SC 13G - Zura Bio Ltd (0001855644) (Subject)
SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
5 - Zura Bio Ltd (0001855644) (Issuer)
5 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00
H.C. Wainwright initiated coverage of Zura Bio Limited with a rating of Neutral and set a new price target of $5.00
Piper Sandler initiated coverage of Zura Bio Limited with a rating of Overweight and set a new price target of $26.00
Ladenburg Thalmann initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $10.00
Oppenheimer initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $17.00
Guggenheim initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $20.00
Chardan Capital Markets initiated coverage of Zura Bio Limited with a rating of Buy and set a new price target of $14.00
Raymond James initiated coverage of Zura Bio Limited with a rating of Strong Buy and set a new price target of $20.00
TibuSHIELD has launched with the activation of its first clinical site This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS) TibuSHIELD will assess tibulizumab over a 28-week study period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, conducted at clinical sites across the United States, Canada, and Europe, with an optional open-label extension (OLE) Topline results for the primary efficacy endpoint at Week 16, along with key secondary and exploratory outcomes, are anticipated in the third quarter of 2026 Zura Bio
Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc) Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025 Strengthened the team with a strategic appointment to support clinical execution and organizational growth $170.6 million in cash and cash equivalents with cash runway anticipated through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial resul
Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation will be available on the News & Events page in the Investors & Media section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the event. ABOUT ZURA BIO Zura Bio is a clinica
TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the launch of TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241223167603/en/Phase 2 TibuSURE study will evaluate tibulizumab in adults with sy
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presentation will be available on the "News & Events" page within the Investors section of the Zura Bio website. The presentation will be archived on the website for at least 30 days following the events. ABOUT ZURA BIO Zura Bio is a c
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A and BAFF, for the treatment of systemic sclerosis (SSc) in adults. "Systemic sclerosis presents significant unmet needs, as current treatments largely target only its interstitial lung disease (ILD) component," said Robert Lisicki,
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in two investor conferences in November. Conference Details: Event: Guggenheim Inaugural Healthcare Innovation Conference Details: Participating in a fireside chat on Tuesday, November 12, 2024, at 1:00 p.m. ET and hosting investor meetings in Boston, MA. Event: Jefferies London Healthcare Conference Details: Hosting investor meetings Thursday, November 21, 2024, in London, UK. Links for live webcasts and replays, if available, will be po
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present at three upcoming investor conferences in September. Conference Details: Event: H.C. Wainwright 26th Annual Global Investment Conference Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET and hosting investor meetings in New York, NY. Event: Stifel Immunology and Inflammation Virtual Summit Details: Presenting on Tuesday, September 17, 2024, at 12:00 p.m. ET and hosting virtual investor meetings. Event: Cantor Global
Presented data for tibulizumab at EULAR 2024, highlighting the potential relevance of dual-inhibition of both IL-17A and BAFF in autoimmune and inflammatory diseases Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in 4Q 2024 and hidradenitis suppurativa (HS) in 2Q 2025 Strengthened management and advisory team with appointment of Robert Lisicki as CEO & formation of Scientific Advisory Board Cash, cash equivalents and investments of $188.4 million as of June 30, 2024, including $112.5 million from private placement executed in April 2024, anticipated to support operations as currently planned through 2027 Zura Bio Limited
Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan On track to initiate Phase 2 study evaluating tibulizumab (ZB-106) for the treatment of systemic sclerosis (SSc) in 2H 2024 Appointment of CEO, Robert Lisicki, underscores Zura Bio's commitment to building leading immunology company as we prioritize excellence in strategic development and scientific planning Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equi
Accomplished biopharmaceutical executives bring invaluable expertise and experience to Zura Bio's Clinical Development programs Executive Leadership hires position Zura Bio for Phase 2 clinical trial readiness across multiple indications in 2024 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointments of Robert Lisicki as President and Chief Operating Officer, and Kiran Nistala, MBBS, PhD, as Executive Vice President Development and Chief Medical Officer, to the Executive Leadership Team. Mr. Lisicki will be responsible for developing an
Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the Board of Directors appointed Arnout Ploos van Amstel as Non-Executive Independent Director by way of co-optation. Mr. Ploos van Amstel replaces Dr. Garry Neil who will continue to support Zura Bio as an advisor on R&D matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231114200703/en/Arnout Ploos van Amstel (Photo: Business Wire) With a career spanning over three decades in the global biotech and pharmaceutical sector, Mr. Ploos van Amstel
Zura Bio Limited (Nasdaq: "ZURA") ("Zura Bio"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the appointment of Michael D. Howell, Ph.D., to the role of Chief Scientific Officer and Head of Translational Science. Dr. Howell brings more than two decades of experience leading discovery, translational research, and early clinical programs and will lead the scientific strategy and translational science efforts at Zura Bio. "I am thrilled to have Michael Howell join our team as our Chief Scientific Officer and Head of Translational Science," said Someit Sidhu, M.D., CEO of Zura Bio. "He brings ov
Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc) Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024 Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS) Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and investments totaling $188.2 million as of September 30, 2024, are anticipated to support operations, as currently planned, through 2027 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter of 2024 and recent corporate updates. "In the third quarter of 2024, we made significant progress toward initiating our first Phase 2 tria
Initiating Phase 2 clinical trials in 2024 to evaluate ZB-106 (tibulizumab) in systemic sclerosis and hidradenitis suppurativa, and ZB-168 in alopecia areata Experienced team building the next Immunology leader Cash position of $103.9 million in cash, cash equivalents and investments is expected to support development and operations into 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio") a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the quarter ended September 30, 2023, and recent business highlights. "In the third quarter, Zura Bio made significant progress
Focused on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist for systemic sclerosis and hidradenitis suppurativa Experienced team building the next immunology leader Cash and cash equivalents of $113 million support development and operations through 2026 Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio" or the "Company"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced its financial results for the second quarter ended June 30, 2023, and recent business highlights. "Zura Bio made great progress in the first half of 2023, and we look forward to advancing
8-K - Zura Bio Ltd (0001855644) (Filer)
SCHEDULE 13G/A - Zura Bio Ltd (0001855644) (Subject)
SCHEDULE 13G - Zura Bio Ltd (0001855644) (Subject)
10-Q - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
DEF 14A - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
10-K - Zura Bio Ltd (0001855644) (Filer)
8-K - Zura Bio Ltd (0001855644) (Filer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)
4 - Zura Bio Ltd (0001855644) (Issuer)